New drug shows promise against fatty liver and scarring
Disease control
Completed
This study tested a drug called saroglitazar magnesium in 189 adults with nonalcoholic steatohepatitis (NASH), a type of fatty liver disease with inflammation and scarring. The goal was to see if the drug could reduce liver inflammation and scarring without making the disease wor…
Phase: PHASE2 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated May 01, 2026 16:01 UTC